All In Biotech

Drug Trial Radar · NCT04799327

The Effect of SHR20004(Noiiglutide ) on Body Weight in Obese Subjects Without Diabetes

A Multi-center, Randomized, Double-blind, Placebo-controlled,Parallel-group Clinical Trial to Assess the Efficacy and Safety of Noiiglutide Injection in Obese Subjects Without Diabetes.

Last checked: Nov 20, 2026Latest source record: Mar 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 254 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

254

Actual

Start

Mar 29, 2021

Primary completion

May 15, 2022

Study completion May 15, 2022

Sponsor

Sponsor type
Industry
First posted
Mar 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to assess the efficacy and safety of SHR20004 on body weight in obese subjects without diabetes.

Conditions

  • Obesity

Interventions

  • SHR20004Drug

    SHR20004:low dose

  • SHR20004Drug

    SHR20004: medium dose

  • SHR20004Drug

    SHR20004: high dose

  • placeboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in body weightTime frame: Week 0, Week 24

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • Shanxi Provincial People's Hospital

    Taiyuan, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.